A prospective observational study of weight loss and change in the modified ferriman-gallwey score in polyendocrine metabolic ovarian syndrome.

Abstract

Objective: To determine whether the magnitude of weight loss over six months was associated with improvement in Modified Ferriman–Gallwey (mFG) score among women with Polyendocrine Metabolic Ovarian Syndrome (PMOS), formerly Polycystic Ovary Syndrome (PCOS). Study Design: Prospective Observational Cohort study. Setting: Combined Military Hospital (CMH), Kharian. Period: December 2025 to June 2026. Methods: Twenty-seven women with PCOS/PMOS who achieved weight loss during six-month follow-up were analyzed. Weight, BMI, and mFG score were recorded monthly. Baseline-to-month-6 changes were assessed using paired tests, longitudinal changes using Friedman tests, and associations between weight loss and mFG improvement using Spearman rank correlation. Results: Mean weight decreased from 82.00±3.46 to 76.00±3.61 kg and BMI from 31.11±2.25 to 28.80±1.99 kg/m² (both p<0.001). Mean mFG score decreased from 18.19±3.06 to 13.67±2.79, with a median improvement of 5 points (IQR 2–6; p<0.001). Mean percentage weight loss was 7.30±2.67%, and 81.5% achieved ≥5% weight loss. Longitudinal changes in weight, BMI, and mFG score were significant (all p<0.001). Percentage weight loss was weakly and non-significantly correlated with mFG improvement (ρ=0.250, p=0.208). Conclusion: Weight, BMI, and mFG scores improved during follow-up; however, greater percentage weight loss was not significantly associated with greater mFG improvement, providing no evidence of a dose-response relationship or causal effect.